ACADIA PHARMACEUTICALS INC 8-K

What Happened

• On May 29, 2026, ACADIA Pharmaceuticals held its 2026 Annual Meeting of Stockholders and announced that stockholders approved an amendment to the company’s 2024 Equity Incentive Plan.
• The amendment increases the aggregate number of shares of common stock authorized for issuance under the Plan by 5,209,670 shares. The Board had previously approved the amendment subject to stockholder approval. The Proxy Statement describing the Plan was filed April 24, 2026.

Key Details

• Amendment approved at the Annual Meeting on May 29, 2026.
• Increase to the Plan’s share reserve: 5,209,670 additional shares.
• Board approval was conditional on stockholder approval; the amended Plan is described in the company’s April 24, 2026 Proxy Statement.
• The amended 2024 Equity Incentive Plan is included as an exhibit to the 8-K (Exhibit 10.1).

Why It Matters

• The approved increase expands the pool of shares ACADIA can grant to employees, directors and consultants under its equity compensation program, supporting hiring, retention and incentive efforts.
• Granting shares from the enlarged pool will dilute existing shareholders as awards vest or options are exercised, which can affect per-share metrics (e.g., EPS) over time.
• Investors should watch future equity grant activity and disclosures (equity compensation expense, share count changes) to assess the timing and financial impact of newly authorized awards.